Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolioGlobeNewsWire • 10/19/26
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness MonthZacks Investment Research • 10/16/26
FDA Approves Genentech's Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)Business Wire • 10/16/26
FDA approves Roche's Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)GlobeNewsWire • 10/16/26
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona TherapeuticsReuters • 10/13/26
Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLAZacks Investment Research • 10/12/26
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer VaccinesZacks Investment Research • 10/12/26
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision LossBusiness Wire • 10/10/26
FDA Approves Genentech's Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon CancerBusiness Wire • 10/09/26
FDA approves Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancerGlobeNewsWire • 10/09/26
Zealand, Roche's obesity drug helps patients lose up to 9.2% weight in mid-stage trialReuters • 10/07/26
Genentech Presents New Data at EURETINA, Highlighting Vabysmo's Real-World Effectiveness and Safety Across Major Retinal ConditionsBusiness Wire • 10/01/26
Genentech's Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of MedicineBusiness Wire • 10/01/26
Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?The Motley Fool • 09/30/26
Roche's fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosisGlobeNewsWire • 09/30/26
Roche Holding AG (RHHBY) Discusses Pharma Strategy, R&D Excellence, AI in Drug Development, and Pipeline Updates Across Key Therapeutic Areas TranscriptSeeking Alpha • 09/29/26
Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, OregonBusiness Wire • 09/28/26